Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Proposed Acquisition of European Medical Testing Subsidiary (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > IIROC Trading Halt - KLY...Reason CTO???
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(20)
•••
Comment by Random1234on Jun 23, 2020 10:51am
104 Views
Post# 31180689

RE:IIROC Trading Halt - KLY...Reason CTO???

RE:IIROC Trading Halt - KLY...Reason CTO???

What does it mean if a public company has a cease trade order (CTO) issued against it?


A cease trade order (CTO) is an order than prohibits trading in securities of a company by the people or companies identified in the order and for the period of time specified in the order. A CTO may prohibit all trading in the securities of a particular company. In general, if you own shares in a company that is subject to a CTO, you will not be able to trade your shares in Ontario.

The OSC may issue a CTO against a company for a number of reasons including:

  • if it files a disclosure document, such as annual financial statements, late - or not at all;
  • if we find that a document contains a significant deficiency; or
  • if, after holding a hearing, the OSC determines it is in the public interest to do so.
In addition, when the length of time required to conduct a hearing could be harmful to the public interest, the OSC can issue a temporary CTO until the hearing is concluded.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities